» Articles » PMID: 34769047

MiRNA-Based Regulation of Alternative RNA Splicing in Metazoans

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Nov 13
PMID 34769047
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Alternative RNA splicing is an important regulatory process used by genes to increase their diversity. This process is mainly executed by specific classes of RNA binding proteins that act in a dosage-dependent manner to include or exclude selected exons in the final transcripts. While these processes are tightly regulated in cells and tissues, little is known on how the dosage of these factors is achieved and maintained. Several recent studies have suggested that alternative RNA splicing may be in part modulated by microRNAs (miRNAs), which are short, non-coding RNAs (~22 nt in length) that inhibit translation of specific mRNA transcripts. As evidenced in tissues and in diseases, such as cancer and neurological disorders, the dysregulation of miRNA pathways disrupts downstream alternative RNA splicing events by altering the dosage of splicing factors involved in RNA splicing. This attractive model suggests that miRNAs can not only influence the dosage of gene expression at the post-transcriptional level but also indirectly interfere in pre-mRNA splicing at the co-transcriptional level. The purpose of this review is to compile and analyze recent studies on miRNAs modulating alternative RNA splicing factors, and how these events contribute to transcript rearrangements in tissue development and disease.

Citing Articles

The interplay between epigenomic and transcriptomic variation during ecotype divergence in stickleback.

Luo M, Zhao J, Merila J, Barrett R, Guo B, Hu J BMC Biol. 2025; 23(1):70.

PMID: 40038570 PMC: 11881503. DOI: 10.1186/s12915-025-02176-0.


Non-Coding RNAs: Novel Regulators of Macrophage Homeostasis in Ocular Vascular Diseases.

Zhang Q, Liu Q, Feng S, Li X, Jiang Q Biomolecules. 2024; 14(3).

PMID: 38540748 PMC: 10968552. DOI: 10.3390/biom14030328.


Cooperation and Competition of RNA Secondary Structure and RNA-Protein Interactions in the Regulation of Alternative Splicing.

Vorobeva M, Skvortsov D, Pervouchine D Acta Naturae. 2024; 15(4):23-31.

PMID: 38234601 PMC: 10790352. DOI: 10.32607/actanaturae.26826.


Polypyrimidine Tract Binding Protein: A Universal Player in Cancer Development.

Gonzalez E, Flatt T, Farooqi M, Johnson L, Ahmed A Curr Mol Med. 2023; 24(12):1450-1460.

PMID: 37877563 DOI: 10.2174/0115665240251370231017053236.


CAG repeat expansion in the Huntington's disease gene shapes linear and circular RNAs biogenesis.

Ayyildiz D, Bergonzoni G, Monziani A, Tripathi T, Doring J, Kerschbamer E PLoS Genet. 2023; 19(10):e1010988.

PMID: 37831730 PMC: 10617732. DOI: 10.1371/journal.pgen.1010988.


References
1.
Liu B, Chai Y, Guo W, Lin K, Chen S, Liu J . MicroRNA-188 aggravates contrast-induced apoptosis by targeting SRSF7 in novel isotonic contrast-induced acute kidney injury rat models and renal tubular epithelial cells. Ann Transl Med. 2019; 7(16):378. PMC: 6736821. DOI: 10.21037/atm.2019.07.20. View

2.
Sun Y, Zhao X, Zhou Y, Hu Y . miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol Rep. 2012; 28(4):1346-52. DOI: 10.3892/or.2012.1958. View

3.
Meseguer S, Mudduluru G, Escamilla J, Allgayer H, Barettino D . MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem. 2010; 286(6):4150-64. PMC: 3039334. DOI: 10.1074/jbc.M110.167817. View

4.
Sokol E, Kedzierska H, Czubaty A, Rybicka B, Rodzik K, Tanski Z . microRNA-mediated regulation of splicing factors SRSF1, SRSF2 and hnRNP A1 in context of their alternatively spliced 3'UTRs. Exp Cell Res. 2018; 363(2):208-217. DOI: 10.1016/j.yexcr.2018.01.009. View

5.
Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View